An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS1 hydromorphone in patients with chronic cancer pain

BMC Palliative Care

Volumn 8, Issue , 2009, Pages

  Hanna, Magdi ^a,b   Tuca, Alberto ^c   Thipphawong, John ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Analgesics and Pain Research   (United Kingdom)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; MORPHINE SULFATE; OROS HYDROMORPHONE; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; BRIEF PAIN INVENTORY; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FEMALE; FEVER; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

EID: 70349832927     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/1472-684X-8-14     Document Type: Article

References (53)

1. Cancer Pain. J Graham M Fletcher-Louis, Decision Resources, Inc 2004 i 175
2. Evidence-based standards for cancer pain management. SM Dy SM Asch A Naeim H Sanati A Walling KA Lorenz, J Clin Oncol 2008 26 23 3879 85 10.1200/JCO.2007.15.9517 18688056
3. Cancer pain management according to WHO analgesic guidelines. SA Schug D Zech U Dorr, J Pain Symptom Manage 1990 5 27 32 10.1016/S0885-3924(05)80006-5 2324558
4. Field-testing of the WHO guidelines for cancer pain relief. Summary report of demonstration projects. V Ventafridda A Caraceni A Gamba, Advances in Pain Research and Therapy New York: Raven Press, Ltd, Foley KM, Bonica JJ, Ventafridda V, 1990 451 64
5. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organization, Technical Report Series 804 Geneva, Switzerland: World Health Organization 1990 1 75
6. Morphine and alternative opioids in cancer pain: the EAPC recommendations. GW Hanks F Conno N Cherny M Hanna E Kalso HJ McQuay S Mercadante J Meynadier P Poulain C Ripamonti L Radbruch JR Casas J Sawe RG Twycross V Ventafridda, Br J Cancer 2001 84 587 93 10.1054/bjoc.2001.1680 11237376
7. American Pain Society, Principles of analgesic use in the treatment of acute pain and cancer pain Glenview, IL: American Pain Society 5 2003
8. Hydromorphone for acute and chronic pain. C Quigley, Cochrane Database Syst Rev 2002 D003447 DOI: 10.1002/14651858.CD003447 11869661
9. Hydromorphone: pharmacology and clinical applications in cancer patients. N Sarhill D Walsh KA Nelson, Support Care Cancer 2001 9 84 96 10.1007/s005200000183 11305075
10. A systematic review of hydromorphone in acute and chronic pain. C Quigley P Wiffen, J Pain Symptom Manage 2003 25 169 78 10.1016/S0885-3924(02)00643-7 12590032
11. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. BH McCarberg RL Barkin, Am J Ther 2001 8 181 86 10.1097/00045391-200105000-00006 11344385
12. Providing constant analgesia with OROS hydromorphone. S Gupta G Sathyan, J Pain Symptom Manage 2007 33 2S 19 S24 10.1016/j.jpainsymman.2006.09.009 (Pubitemid 46186874)
13. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. MS Angst DR Drover J Lotsch B Ramaswamy S Naidu D Wada D Stanski, Anesthesiology 2001 94 63 73 10.1097/00000542-200101000-00014 11135723
14. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. DR Drover MS Angst M Valle B Ramaswamy S Naidu DR Stanski D Verotta, Anesthesiology 2002 97 827 36 10.1097/00000542-200210000-00013 12357147
15. Summary of product characteristics for JURNISTA. ALZA corporation, Mountain view, CA
16. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. G Sathyan E Xu J Thipphawong SK Gupta, BMC Clin Pharmacol 2007 7 3 10.1186/1472-6904-7-3 17270058
17. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study). DM Bass M Prevo DS Waxman, Drug Saf 2002 25 1021 33 10.2165/00002018-200225140-00004 12408733
18. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. G Sathyan E Xu J Thipphawong SK Gupta, BMC Clin Pharmacol 2007 7 2 10.1186/1472-6904-7-2 17270055
19. Pharmacokinetic profile of 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. G Sathyan K Sivakumar J Thipphawong, Curr Med Res Opin 2008 24 1 297 305 10.1185/030079908X253861 18062845
20. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. M Palangio DW Northfelt RK Portenoy D Brookoff RTJr Doyle BE Dornseif MC Damask, J Pain Symptom Manage 2002 23 355 68 10.1016/S0885-3924(02)00390-1 12007754
21. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. M Wallace RL Rauck D Moulin J Thipphawong S Khanna IC Tudor, J Int Med Res 2008 36 2 343 52 18380946
22. 1 hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. M Wallace RL Rauck D Moulin J Thipphawong S Khanna IC Tudor, In J Clin Pract 2007 61 10 1671 6 10.1111/j.1742-1241.2007.01500.x (Pubitemid 47404391)
23. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in male and female subjects. C Durnin ID Hind SP Ghani DB Yates J Gegg, Proc West Pharmacol Soc 2001 44 77 8 11794002
24. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in young and elderly subjects. C Durnin ID Hind SP Ghani DB Yates M Cross, Proc West Pharmacol Soc 2001 44 79 80 11794003 (Pubitemid 34087720)
25. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. MA Lee ME Leng EJ Tiernan, Palliat Med 2001 15 1 26 34 10.1191/026921601669626431 11212464
26. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. SN Davison PR Mayo, J Opioid Manag 2008 4 6 339 44
27. Opioids in renal failure and dialysis patients. M Dean, J Pain Symptom Manage 2004 28 5 497 504 10.1016/j.jpainsymman.2004.02.021 15504625
28. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. EJ Murphy, Anaesth Intensive Care 2005 33 3 311 22 15973913
29. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. C Durnin ID Hind SP Ghani DB Yates KH Molz, Proc West Pharmacol Soc 2001 44 83 4 11794005
30. Role of human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. SA Benetton VM Borges TK Chang KM McErlane, Xenobiotica 2004 34 4 335 44 10.1080/00498250310001657559 15268978
31. Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. M Zheng KM McErlane MC Ong, Xenobiotica 2002 32 5 427 39 10.1080/00498250110119090 12065064
32. Biopharmaceutic parameters of hydromorphone and in-vitro evaluation of its tablet and suppository dosage form. PV Parab DE Coyle WH Streng DD Denson WA Ritschel, Pharm Ind 1987 49 951 65
33. Hydromorphone. A Murray NA Hagen, J Pain Symptom Manage 2005 29 5 Suppl 57 66 10.1016/j.jpainsymman.2005.01.007 15907647
34. 1 hydromorphone and controlled-release morphine for the control of chronic cancer pain. M Hanna J Thipphawong the 118 study group, BMC Palliat Care 2008 7 17 18976472
35. 1 hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomised, open-label, noninferiority analysis. M Hale IC Tudor S Khanna J Thipphawong, Clin Ther 2007 29 5 874 88 10.1016/j.clinthera.2007.05.016 17697906
36. Sustained-release opioids on the test stand. D Uhl, Deutsche Apotheker Zeitung 2008 148 1/2 69 73
37. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. R Likar H Kayser R Sittl, Clin Ther 2006 28 6 943 52 10.1016/j.clinthera.2006.06.012 16860176
38. Advances in the therapy of cancer pain: from novel experimental models to evidence-based treatments. CD Sarantopoulos, Signa Vitae 2007 2 Suppl 1 23 41
39. Opioid analgesia: perspectives on right use and utility. JC Ballantyne, Pain Physician 2007 10 3 479 91 17525783
40. Advances in cancer pain management. FJ McDonnell JW Sloan SR Hamann, Curr Pain Headache Rep 2001 5 3 265 71 10.1007/s11916-001-0041-y 11309214
41. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. K Mystakidou E Parpa E Tsilika E Katsouda V Kouloulias J Kouvaris S Georgaki L Vlahos, J Pain 2004 5 2 119 32 10.1016/j.jpain.2003.12.003 15042520
42. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. J Menten M Desmedt D Lossignol A Mullie, Curr Med Res Opin 2002 18 8 488 98 10.1185/030079902125001272 12564660
43. Hydromorphone: pharmacology and clinical applications in cancer patients. N Sarhill D Walsh KA Nelson, Support Care Cancer 2001 9 84 96 10.1007/s005200000183 11305075
44. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. P Lawlor K Turner J Hanson E Bruera, Pain 1997 72 1-2 79 85 10.1016/S0304-3959(97)00018-3 9272790
45. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. E Bruera J Pereira S Watanabe M Belzile N Kuehn J Hanson, Cancer 1996 78 4 852 7 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR233.0.CO;2-T 8756381
46. Subcutaneous infusions for control of cancer symptoms. P Storey HH Hill Jr RH St Louis EE Tarver, J Pain Symptom Manage 1990 5 33 41 10.1016/S0885-3924(05)80007-7 1969887
47. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. RL Daut CS Cleeland RC Flanery, Pain 1983 17 197 210 10.1016/0304-3959(83)90143-4 6646795
48. Effects of controlled-released morphine on quality of life for cancer pain. B Ferrell C Wisdom C Wenzl J Brown, Oncol Nurs Forum 1989 16 521 6 2755859
49. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. S Wirz HC Wartenberg J Nadstawek, Support Care Cancer 2008 16 9 999 1009 10.1007/s00520-007-0368-y 18095008
50. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial. S Wirz HC Wartenberg C Elsen M Wittmann M Diederichs J Nadstawek, Clin J Pain 2006 22 9 770 5 10.1097/01.ajp.0000210925.33783.4d 17057558
51. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. SM Weinstein M Shi BJ Buckley MA Kwarcinski, Clin Ther 2006 28 86 98 10.1016/j.clinthera.2006.01.010 16490582
52. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pereira P Lawlor A Vigano M Dorgan E Bruera, J Pain Symptom Manage 2001 22 2 672 87 10.1016/S0885-3924(01)00294-9 11495714
53. Opioid conversion guidelines for managing adult cancer pain. SA Derby, Am J Nurs 1999 99 10 62 5 10.2307/3521920 10542852